600 patients66,869 observations120 daysLIVE

Patient P-01624

Synthetic patientNBL-101 · Day 115 · 55–64 · M · baseline S14Open companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
61%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 31 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 32 Patient acceptedStarted NP-02 in the companion
  4. Day 42 Trajectory diverged from predictionObserved response fell below the model's expected path.
  5. Day 42 GI symptom burden −11% vs expectedDietary Support Protocol NP-02
  6. Day 48 Tolerance state changedUnstable → Improving
  7. Day 58 ME-01 recommendedMonitoring Escalation ME-01
  8. Day 59 GI-04 recommendedGI Support Protocol GI-04
  9. Day 59 Patient acceptedStarted ME-01 in the companion
  10. Day 60 Patient acceptedStarted GI-04 in the companion
  11. Day 62 Deterioration detected before clinical escalationMonitoring Escalation ME-01
  12. Day 68 GI symptom burden −24% vs expectedGI Support Protocol GI-04
  13. Day 74 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 42.

Primary contributors, last 14 days
  • Nutritional resilience-10
  • Inflammatory activity-7
  • Treatment adherence-2
  • Toxicity-2

What helped?

  • Dietary Support Protocol NP-02Day 31
    Result: symptom burden −11%
  • Monitoring Escalation ME-01Day 58
    Result: deterioration detected before clinical escalation
  • GI Support Protocol GI-04Day 59
    Result: symptom burden −24%
LIFE OS recommendation
Supportive Compound SC-12
62%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 81% showed improvement
  • median effect visible after 6 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Inflammatory signalling 85
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 47
    • WearableHRV 23 ms, trending down
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 35/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 44
  • Mucosal barrier integrity 30
    • MicrobiomeAkkermansia low → thinner mucus layer
  • Autonomic recovery 20
    • Wearable2,574 steps/day
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 1.8 · butyrate capacity 35/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
23 ms
Sleep
7.2 h
Steps
2,293
Resting HR
65 bpm
Daily log: GI score 43, nutritional resilience 40, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0187967%S14SC-12improved51
P-0162758%S14GI-04improved54
P-0170658%S14GI-04improved55
P-0146255%S14NP-02improved47
P-0133653%S03GI-04improved51
P-0157353%S14GI-04improved49
P-0139352%S14GI-04improved53
P-0143851%S14GI-04improved56
P-0155651%S14GI-04improved44
P-0166151%S03GI-04improved52
P-0140050%S17GI-04improved51
P-0143150%S14GI-04improved41